Research Use Only. Not for human or veterinary use.
Nexaflow Research

Research insight

Published literature

Records for the compounds in this catalogue, retrieved from PubMed and refreshed weekly. Every entry carries its PubMed identifier and, where one exists, its DOI, so it can be followed to the source.

51
records listed
10
compounds covered
Weekly
refreshed from PubMed
2026-10-12
last retrieved

4 records

BPC-157

Product →
  1. No figure under an open licence
    2026

    BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

    Demirtaş H · International journal of molecular sciences

    PMID 42794771

  2. No figure under an open licence
    2026

    Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.

    Willis J, Vu N · International journal of pharmaceutical compounding

    PMID 42752426

  3. No figure under an open licence
    2026

    Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.

    Zhang H, et al. · Applied biochemistry and biotechnology

    PMID 42667535

  4. No figure under an open licence
    2026

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.

    Luansritisakul C, et al. · Current pain and headache reports

    PMID 42635865

4 records

CJC-1295 (No DAC)

Product →
  1. No figure under an open licence
    2026

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    Dominikowski A, et al. · Frontiers in endocrinology

    PMID 42395176

  2. No figure under an open licence
    2026

    Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

    Renke G, Chinellato L · International journal of molecular sciences

    PMID 42123471

  3. No figure under an open licence
    2026

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych V, et al. · Frontiers in aging

    PMID 42021992

  4. No figure under an open licence
    2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.)

    PMID 41966639

6 records

Epithalon

  1. No figure under an open licence
    2026

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman OF, et al. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

    PMID 41490200

  2. Chemical formula of Epitalon proposed by most authors (a) and rarely mentioned "double-gamma bonded" structure (b).
    2025

    Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.

    Araj SK, et al. · International journal of molecular sciences

    Figure: Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. International Journal of Molecular Sciences, 2025. CC BY.

    PMID 40141333

  3. No figure under an open licence
    2024

    [Peptidergic regulation of expression of cellular aging marker proteins in buccal epithelium.].

    Ivko OM, et al. · Advances in gerontology = Uspekhi gerontologii

    PMID 39742404

  4. No figure under an open licence
    2015

    Effects of Geroprotectors on Age-Related Changes in Proteolytic Digestive Enzyme Activities at Different Lighting Conditions.

    Morozov AV, et al. · Bulletin of experimental biology and medicine

    PMID 26519279

  5. No figure under an open licence
    2013

    [Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

    Dzhokhadze TA, et al. · Georgian medical news

    PMID 24423684

  6. No figure under an open licence
    2013

    [Genome instability in pulmonary tuberculosis before and after treatment].

    Dzhokhadze TA, et al. · Georgian medical news

    PMID 24323970

5 records

GHK-Cu

  1. Evidence-selection workflow for a systematic evidence map, reporting identification, screening, eligibility and inclusion.
    2026

    GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.

    Mateescu DM, et al. · Pharmaceutics

    Figure: Mateescu DM, Gavrilescu DM, Mincioaga RI, Pah AM, Toma AO, Serban DV, Avram CA, Craciun ML, Enache B, Muresan CO. Pharmaceutics, 2026. CC BY.

    PMID 42797253

  2. PRISMA 2020 flow diagram and stratification of included studies by model type.
    2026

    A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.

    Najafi N, et al. · Archives of internal medicine research

    Figure: Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. Archives of Internal Medicine Research, 2026. CC BY.

    PMID 42787770

  3. No figure under an open licence
    2026

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.

    Luansritisakul C, et al. · Current pain and headache reports

    PMID 42635865

  4. No figure under an open licence
    2026

    The Regenerative Potential of GHK-Cu in Aesthetic Medicine.

    Mokhtar J, et al. · Aesthetic surgery journal

    PMID 42619529

  5. No figure under an open licence
    2026

    A tea exosome-integrated self‑oxygenating cascade chitosan/oxidized alginate hydrogel for remodeling the hyperglycemic and hypoxic microenvironment in diabetic wound healing.

    Xie LH, et al. · Carbohydrate polymers

    PMID 42586657

4 records

Ipamorelin

  1. No figure under an open licence
    2026

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    Dominikowski A, et al. · Frontiers in endocrinology

    PMID 42395176

  2. No figure under an open licence
    2026

    Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

    Renke G, Chinellato L · International journal of molecular sciences

    PMID 42123471

  3. No figure under an open licence
    2026

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych V, et al. · Frontiers in aging

    PMID 42021992

  4. No figure under an open licence
    2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.)

    PMID 41966639

6 records

KPV

  1. No figure under an open licence
    2026

    Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages.

    Bai JS, et al. · Tissue & cell

    PMID 42854645

  2. No figure under an open licence
    2026

    Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.

    Willis J, Vu N · International journal of pharmaceutical compounding

    PMID 42752426

  3. No figure under an open licence
    2026

    KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.

    An SH, et al. · Tissue & cell

    PMID 42585803

  4. No figure under an open licence
    2026

    Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.

    Lee JY, et al. · Cytotechnology

    PMID 42064835

  5. Design strategies for inflammation-responsive, self-immolative peptide prodrugs and characterization of a peptide KPV prodrug conjugate.
    2026

    Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.

    Cheng J, et al. · Science advances

    Figure: Cheng J, Wu P, Li C, Han Y, Sun M, Dou Y, Chen S, Zhang J. Science Advances, 2026. CC BY.

    PMID 41533788

  6. No figure under an open licence
    2025

    Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

    Rodrigues JM, et al. · Drug discovery today

    PMID 41241376

6 records

MOTS-c

  1. No figure under an open licence
    2026

    MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis.

    Sun J, et al. · Chinese medical journal

    PMID 42767971

  2. No figure under an open licence
    2026

    Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.

    Willis J, Vu N · International journal of pharmaceutical compounding

    PMID 42752426

  3. No figure under an open licence
    2026

    Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications.

    Kurian GA · Journal of bioenergetics and biomembranes

    PMID 42734848

  4. No figure under an open licence
    2026

    Correction: Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.

    Kutuk IS, et al. · Scientific reports

    PMID 42716952

  5. Box plots of serum concentrations of advanced glycation end products, soluble receptor for advanced glycation end products, their ratio, and endogenous secretory receptor.
    2026

    AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition.

    Suliman ME, et al. · Antioxidants (Basel, Switzerland)

    Figure: Suliman ME, Rahman A, Qureshi AR, Barany P, Stenvinkel P, Kublickiene K, Lindholm B. Antioxidants, 2026. CC BY.

    PMID 42650220

  6. No figure under an open licence
    2026

    Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review.

    Ayubi N, et al. · Physiology international

    PMID 42640735

6 records

Selank

  1. No figure under an open licence
    2026

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman OF, et al. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

    PMID 41490200

  2. No figure under an open licence
    2022

    Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

    Konstantinopolsky MA, et al. · Bulletin of experimental biology and medicine

    PMID 36322304

  3. No figure under an open licence
    2021

    Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.

    Doyno CR, White CM · Journal of clinical pharmacology

    PMID 34396551

  4. No figure under an open licence
    2021

    The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

    Leonidovna YA, et al. · Current reviews in clinical and experimental pharmacology

    PMID 32621722

  5. No figure under an open licence
    2020

    Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

    Mukhina AY, et al. · Bulletin of experimental biology and medicine

    PMID 32651826

  6. No figure under an open licence
    2020

    Functional Connectomic Approach to Studying Selank and Semax Effects.

    Panikratova YR, et al. · Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections

    PMID 32342318

6 records

Semax

  1. No figure under an open licence
    2026

    Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.

    Willis J, Vu N · International journal of pharmaceutical compounding

    PMID 42752426

  2. No figure under an open licence
    2026

    Quantitative MRI Pharmacokinetic Modeling and MALDI Mass Spectrometry Imaging Biodistribution of a pH Mapping MRI Contrast Agent.

    Mohanta Z, et al. · Theranostics

    PMID 42559144

  3. No figure under an open licence
    2026

    [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].

    Sheludchenko VM, et al. · Vestnik oftalmologii

    PMID 42366656

  4. Experimental setup of the magnetic field shielding performance test, the test system, and the structure of a single shield layer.
    2026

    Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons.

    Liang Y, et al. · Materials (Basel, Switzerland)

    Figure: Liang Y, Liu B, Ma H, Pan L, He A, Dong Y, Man Q, Li J. Materials, 2026. CC BY.

    PMID 42195624

  5. No figure under an open licence
    2026

    Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.

    Arcos I, et al. · Journal of clinical medicine

    PMID 42074872

  6. No figure under an open licence
    2026

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych V, et al. · Frontiers in aging

    PMID 42021992

4 records

TB-500 (Thymosin β4 acetate)

Product →
  1. No figure under an open licence
    2026

    Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.

    Willis J, Vu N · International journal of pharmaceutical compounding

    PMID 42752426

  2. No figure under an open licence
    2026

    Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.

    Luansritisakul C, et al. · Current pain and headache reports

    PMID 42635865

  3. No figure under an open licence
    2026

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.

    Biçer O, et al. · Joint diseases and related surgery

    PMID 42542926

  4. No figure under an open licence
    2026

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych V, et al. · Frontiers in aging

    PMID 42021992

Research Use Only. Not for human or veterinary use.

These materials are supplied to laboratories and research organisations as reagents. They are not medicines, are not supplied for administration to humans or animals, and must not be resold for those purposes.